New Delhi: India’s pharmacy industry is achieving new heights in the US market. India’s leading pharmaceutical company Sun Pharma has proposed 11.75‑billion‑dollar acquisition of US‑based Organon.
Sharing a news report, former NITI Aayog CEO Amitabh Kant writes on social media platform X, “Sun Pharma’s proposed 11.75‑billion‑dollar acquisition of US‑based Organon is a coming‑of‑age moment for Indian pharma on the global stage.”
Amitabh Kant further writes, “It will put India’s largest drugmaker firmly within the global top 25, with exposure to women’s health and biosimilars across roughly 140 countries. Beyond scaling up revenues, this acquisition will sharpen capabilities, and signals strong confidence in India’s R&D and manufacturing strength. A crucial foothold in the US market.”
Sun Pharma’s proposed 11.75‑billion‑dollar acquisition of US‑based Organon is a coming‑of‑age moment for Indian pharma on the global stage. It will put India’s largest drugmaker firmly within the global top 25, with exposure to women’s health and biosimilars across roughly 140… pic.twitter.com/LAUFnsPYVH
— Amitabh Kant (@amitabhk87) April 28, 2026
Sun Pharma is the world’s leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.
